Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Breast Cancer Research and Treatment
Erschienen in: Breast Cancer Research and Treatment 3/2013

01.12.2013 | Clinical trial

Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients

verfasst von: R. Wolters, A. Wöckel, W. Janni, I. Novopashenny, F. Ebner, R. Kreienberg, M. Wischnewsky, L. Schwentner, For the BRENDA Study Group

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Multifocal (MF) and multicentric (MC) breast cancers have been comprehensively studied, and their outcomes have been compared with unifocal (UF) tumors. We attempted to answer the following questions: (1) Does MF/MC presentation influence the outcome concerning BC mortality?, (2) Is there an impact of guideline-adherent adjuvant treatment in these BC subtypes?, and (3)What is the influence of guideline violations concerning surgery (breast-conserving surgery versus mastectomy) on the survival of MF/MC BC patients? Between 1992 and 2008, we retrospectively analyzed 8,935 breast cancer patients from 17 participating breast cancer centers within the BRENDA study group. Of 8,935 breast cancer patients, 7,073 (79.2 %) had UF tumors, 1,398 (15.6 %) had MF tumors, and 464 (5.2 %) had MC tumors. RFS was significantly worse for MF/MC BC patients compared to patients with UF tumors (MF p = 0.007; MC p = 0.019). OAS was significantly worse for MC patients but not for MF patients compared to patients with UF tumors (MF p = 0.321; MC p = 0.001). Guideline adherence was significantly lower in patients with MF (n = 580; 41.5 %) and MC (n = 204; 44.0 %) compared to patients with UF (n = 3,871; 54.7 %) (p < 0.001) tumors. Guideline violations were associated with a highly significant deterioration in survival throughout all subgroups except for MC, with respect to RFS and OAS. For 100 %-guideline-adherent patients, we could not find any significant differences in RFS and OAS after adjusting by nodal status, grade, and tumor size. Furthermore, we could not find any significant differences in RFS and OAS in patients with MF or MC stratified by breast-conserving therapy (BCT lumpectomy and radiation therapy) and mastectomy. There is a strong association between improved RFS and OAS in patients with MF/MZ BC. There are no significant differences in RFS and OAS for patients with breast-conserving therapy or mastectomy.
Literatur
1.
Rakha EA, Ellis IO (2009) Triple-negative/basal-like breast cancer: review. Pathology 41(1):40–47PubMedCrossRef
2.
Ihemelandu CU, Lefall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA (2007) Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Res 143(1):109–118PubMedCrossRef
3.
Wiechmann L, Sampson M, Stempel M, Jacks LM, Patil SM, King T, Morrow M (2009) Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol 16(10):2705–2710PubMedCrossRef
4.
Ibrahim E, Al-Gahmi AM, Zeenelin AA, Zekri JM, Elkhodary TR, Gaballa HE, Fawzy EE, El Sayed ME, Alzahrani MS (2009) Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and Her-2 as surrogate markers. Med Oncol 26(3):372–378PubMedCrossRef
5.
Lynch SP, Lei X, Chavez-MacGregor M, Hsu L, Meric-Bernstam F, Buchholz TA, Zhang A, Hortobagyi GN, Valero V, Gonzalez-Angulo AM (2012) Multifocality and multicentricity in breast cancer and survival outcomes. Ann Oncol 23(12):3063–3069PubMedCrossRef
6.
Yerushalmi R, Kennecke H, Woods R, Olivotto IA, Speers C, Gelmon KA (2009) Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence. Breast Cancer Res Treat 117(2):365–370PubMedCrossRef
7.
Egan RL (1982) Multicentric breast carcinomas: clinical-radiographic-pathologic whole organ studies and 10-year survival. Cancer 49:1123–1130PubMedCrossRef
8.
Wilkinson LS, Given-Wilson R, Hall T, Potts H, Sharma AK, Smith E (2005) Increasing the diagnosis of multifocal primary breast cancer by the use of bilateral whole-breast ultrasound. Clin Radiol 60(5):573–578PubMedCrossRef
9.
Sardanelli F, Giuseppetti GM, Panizza P, Bazzocchi M, Fausto A, Simonetti G, Lattanzio V, Del Maschio A (2004) Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer in fatty and dense breasts using the whole-breast pathologic examination as a gold standard. AJR Am J Roentgenol 183:1149–1157PubMedCrossRef
10.
Houssami N, Ciatto S, Macaskill P, Lord SJ, Warren RM, Dixon JM, Irwig L (2008) Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol 26(19):3248–3258PubMedCrossRef
11.
Cabioglu N, Ozmen V, Kaya H, Tuzlali S, Igci A, Muslumanoglu M, Kecer M, Dagoglu T (2009) Increased lymph node positivity in multifocal and multicentric breast cancer. J Am Coll Surg 208(1):67–74PubMedCrossRef
12.
Andea AA, Wallis T, Newman LA, Bouwman D, Dey J, Visscher DW (2002) Pathologic analysis o tumor size and lymph node status in multifocal/multicentric breast carcinoma. Cancer 94(5):1383–1390PubMedCrossRef
13.
Pedersen L, Gunnarsdottir KA, Rasmussen BB, Moeller S, Lanng C (2004) The prognostic influence of multifocality in breast cancer patients. Breast 13(3):188–193PubMedCrossRef
14.
Weissenbacher TM, Zschage M, Janni W, Jeschke U, Dimpfl T, Mayr D, Rack B, Schindlbeck C, Friese K, Dian D (2010) Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified? Breast Cancer Res Treat 122(1):27–34PubMedCrossRef
15.
Rezo A, Dahlstrom J, Shadbolt B, Rodins K, Zhang Y, Davis AJ (2011) Tumor size and survival in multicentric and multifocal breast cancer. Breast 20(3):259–263PubMedCrossRef
16.
Tot T, Gere M, Pekar G, Tarjan M, Hofmeyer S, Hellberg D, Lindquist D, Chen TH, Yen AM, Chiu SY, Tabar L (2011) Breast cancer multifocality, disease extent, and survival. Human Pathol 42:1761–1769CrossRef
17.
Litton JK, Eralp Y, Gonzalez-Angulo AM, Broglio K, Uyei A, Hortobagyi GN, Arun B (2007) Multifocal breast cancer in women < or =35 years old. Cancer 110(7):1445–1450PubMedCrossRef
18.
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC Cancer staging manual. Springer, New York
19.
Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, Kleer C, O`Malley FP, Page DL, Smith BL, Tan LK, Weaver DL, Winer E (2009) Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med 133:1515–1538PubMed
20.
Schouten LJ, Jager JJ, van den Brandt PA (1993) Quality of cancer registry data: a comparison of data provided by clinicians with those of registrations personnel. Br J Cancer 68(5):974–977PubMedCrossRef
21.
Wolters R, Regierer AC, Schwentner L, Geyer V, Possinger K, Kreienberg R, Wischnewsky MB, Wöckel A (2012) A comparision of international breast cancer guidelines-Do the national guidelines differ in treatment recommendations? Eur J Cancer 48(1):1–11PubMedCrossRef
22.
Kreienberg R, Kopp I, Albert U et al (2008) Interdisciplinary S3 guideline for diagnosis and therapy of breast cancer in women. German Cancer Society, Berlin
23.
Boyages J, Jayasinghe UW, Coombs N (2010) Multifocal breast cancer and survival: each focus does matter particularly for larger tumors. Eur J Cancer 46:1990–1996PubMedCrossRef
24.
Hamaker ME, Schreurs WH, Uppelschoten JM, Smorenburg CH (2009) Breast cancer in the elderly: retrospective study on diagnosis and treatment according to national guidelines. Breast J 15:26–33PubMedCrossRef
25.
Schwentner L, Wolters R, Wischnewsky MB, Kreienberg R, Wöckel A (2012) Survival of patients with bilateral versus unilateral breast cancer and impact of guideline adherent adjuvant treatment: a multi-centre cohort study of 5,292 patients. Breast 21(2):171–177PubMedCrossRef
26.
Schwentner L, Wolters R, Koretz K, Wischnewsky MB, Kreienberg R, Rottscholl R, Wöckel A (2012) Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival-a retrospective multi-centre cohort study. Breast Cancer Res Treat 132(3):1073–1080PubMedCrossRef
27.
Hancke K, Denkinger MD, König J, Kurzeder C, Wöckel A, Herr D, Blettner M, Kreienberg R (2010) Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German Clinical Cohort Study. Ann Oncol 21(4):748–753PubMedCrossRef
28.
Janssen-Heijnen ML, Maas HA, Lemmens VE, Houterman S, Louwman WJ, Verheij CD, Coebergh JW (2005) The correlation of age and comorbidity with therapy and survival in cancer patients in North-Brabant and North-Limburg, 1995–2001. Ned Tijdschr Geneeskd 149(30):1686–1690PubMed
29.
DeMichele A, Putt M, Zhang Y, Glick JH, Norman S (2003) Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patients. Cancer 97(9):2150–2159PubMedCrossRef
30.
Craft PS, Buckingham JM, Dahlstrom JE, Beckmann KR, Zhang Y, Stuart-Harris R, Jacob G, Roder D, Tait N (2010) Variation in the management of early breast cancer in rural and metropolitan centres: implications fort he organisation of rural cancer services. Breast 19(5):396–401PubMedCrossRef
31.
Hebert-Croteau N, Brisson J, Latreille J, Rivard M, Abdelaziz N, Martin G (2004) Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with nodal negative breast cancer. J Clinical Oncol 22:3685–3693CrossRef
32.
Gentilini O, Botteri E, Rotmensz N, Da Lima L, Caliskan M, Garcia-Etienne CA, Sosnovskikh I, Intra M, Mazzarol G, Musmeci S, Veronesi P, Galimberti V, Luini A, Viale g, Goldhirsch A, Veronesi U (2009) Conservative surgery in patients with multifocal/multicentric breast cancer. Breast Cancer Res Treat 113(3):577–583
33.
Yerushalmi R, Tyldesley S, Woods R, Kennecke HF, Speers C, Gelmon KA (2012) Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality? Ann Oncol 23(4):876–881
34.
Bauman L, Barth RJ, Rosenkranz KM (2010) Breast conservation in women with multifocal-multicentric breast cancer: is it feasible? Ann Surg Oncol 17(3):325–329
35.
Chung AP, Huynh K, Kidner T, Mirzadehgan P, Sim MS, Giuliano AE (2012) Comparision of outcomes of breast conserving therapy in multifocal and unifocal invasive breast cancer. J Am Coll Surg 215(1):137–146
Metadaten
Titel
Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients
verfasst von
R. Wolters
A. Wöckel
W. Janni
I. Novopashenny
F. Ebner
R. Kreienberg
M. Wischnewsky
L. Schwentner
For the BRENDA Study Group
Publikationsdatum
01.12.2013
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2013
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2772-y

Weitere Artikel der Ausgabe 3/2013

Breast Cancer Research and Treatment 3/2013 Zur Ausgabe

Brief Report

Cardiovascular disease among breast cancer survivors: the call for a clinical vascular health toolbox

Epidemiology

Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral

Clinical trial

Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer

Brief Report

Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer

Events

Acknowledgement of reviewers 2013

Review

Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998–2002

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise